Cost avoidance using linezolid for methicillin-resistant Staphylococcus aureus infections in a specialist diabetes foot clinic | Zendy

Matthew J. Young | Zendy; G R Hodges | Zendy; Joanne McCardle | Zendy

Open Access

Cost avoidance using linezolid for methicillin-resistant Staphylococcus aureus infections in a specialist diabetes foot clinic

Author(s) -

Matthew J. Young,

G R Hodges,

Joanne McCardle

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks323

Subject(s) - linezolid , medicine , diabetic foot , diabetes mellitus , foot (prosody) , staphylococcus aureus , antibiotics , emergency medicine , surgery , intensive care medicine , vancomycin , microbiology and biotechnology , linguistics , philosophy , endocrinology , biology , bacteria , genetics

An audit was performed to determine whether linezolid (Zyvox, Pharmacia Limited, Sandwich, UK) was being used in accordance with local guidelines and if this had an effect on admissions for diabetes foot ulceration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research